Global heparin market is expected to grow at a CAGR of 5.7% in the forecast period of 2019 to 2026. The years considered for study are as mentioned below.
Access Full Report at https://databridgemarketresearch.com/reports/global-heparin-market
Heparin is used to prevent and treat blood clotting disorders. It is also used to prevent blood clots formation post-surgery and during dialysis, and blood sample collection for diagnostic tests. It helps in unit erupted blood flowing by releasing anti-clotting protein, known as an anticoagulant. It is also used in diagnose and treatment of disseminated intravascular coagulation, deep vein thrombosis, pulmonary embolism, and arterial thromboembolism. It cannot dissolve blood clots but only prevent the clots formation which may lead to more serious problems. Heparin is an animal-derived product extracted from mucosal tissues of slaughtered meat animals. The application of heparin includes diagnosis of heart attacks and unstable angina, inhibition of cancer, metabolic disorders, and hepatitis, as an anti-inflammatory drug in injuries, heparin is used as anti-coagulants.
The market has witness developments in terms of merger and acquisitions, partnerships or product launches to enhance the product portfolio to meet the rising demand for heparin. For instance, in December 2016, Fresenius Kabi (Germany) launched Heparin Sodium Injection 5,000 USP units/mL. It is an anticoagulant used to prevent clotting of blood and the formation of fibrin clots both in vitro and in vivo. This product launch provided extensive range of heparin products in the global market.
Sanofi dominated global heparin market. The other key players existing in the market includes Pfizer Inc, Fresenius KABI AG, F. Hoffmann-La Roche Ltd, Mylan N.V., Aspen Holdings The other key players existing in the market includes Changzhaou Qianhong Bio-pharma Co., ltd., Eisai Co., Ltd., Hebei Changshan Biochemical Pharmaceutical Co. Ltd., Hikma Pharmaceuticals PLC, LEO Pharma A/S, Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd., Novartis AG, OPOCRIN S.P.A, SARIA SE & Co. KG, Shanghai Fosun Pharmaceutical (Group) Co., Ltd, Shenzhen Hepalink Pharmaceutical Group Co., Ltd., Shenzhen Techdow Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., Yino Pharma Limited.
Sanofi:
Sanofi headquartered in Paris, France and it was founded in 2004. The company is engaged in development, manufacture and sales pharmaceuticals, consumer health care, and vaccines. The company is providing products in three products categories pharmaceutical products, vaccines, consumer health products. The market focused category lies under pharmaceutical products. The company has three operating Business categories pharmaceuticals, consumer health and vaccines. The market focused category lies under pharmaceuticals category. The company has global presence in Europe, America, Asia-Pacific, Middle East and Africa regions. The company is continuously engaged in strategic relationship to enhance the production and manufacturing of the heparin.
- In September 2018, the company announced Health Canada’s approval of a new indication for Lovenox (enoxaparin sodium) for the prevention of thrombus formation in the extra-corporeal circulation during haemodialysis in patients with end stage kidney disease (ESKD). This will attract the potential consumers helping in the growth of the company.
It has its global networks through direct sales representatives and distributors in around the world. The company has various subsidiaries such as Sanofi Pasteur SA (France), Genzyme Corporation (U.S), Genzyme Therapeutics Products LP (U.S), Sanofi Pasteur Limited (Canada), Genzyme Flanders BVBA Holding Co (Belgium) and among others.
Pfizer Inc.:
Pfizer Inc. is headquartered in New York, U.S. founded in 1849. The company is engaged in in the discovery, development, manufacturing and sells of healthcare products worldwide. Pfizer Inc. operates through two business segments which include IH (Innovative Health Segment), EH (Essential Health Segment). The market focused category lies under IH (Innovative Health Segment) category.
The company is continuously engaged in strategic relationship to enhance the production and manufacturing of the heparin such as,
- In February 2015, Pfizer Inc. spent USD 17,000 million to acquire Hospira which deals with biosimilar—generic versions of biologic drugs, made from living cells biologic drugs. The deal includes the commercial rights for anticoagulant heparin sodium which will help the company in generating the revenue and growth in the heparin market.
The company has wide geographic presence in North America, South America, Europe, Asia Pacific, and Middle East & Africa. It operates through its subsidiaries such as Warner-Lambert Company LLC (U.S.), Pfizer Enterprises SARL (Luxembourg), Pfizer Luxembourg SARL (Luxembourg), Pfizer Investment Co. Ltd. (China), Wyeth Lederle S.p.A. (Italy) and among others.
Fresenius KABI AG:
Fresenius KABI AG headquartered in Bad Homburg, Germany was founded in 1999. The company is engaged in in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The products and services are used to help critically and chronically ill patients. Fresenius KABI AG offers various innovative solutions for better Life such as standard solutions, animal health, colloids, compounding, infusion technology, IV drugs, parenteral nutrition, and transfusion technology. The market focused category lies under IV drugs, standard solutions category. The company operates through four business segments which include IV Drugs, clinical nutrition, infusion technology, medical devices/transfusion. The market focused category lies under IV drugs category.
The company has global presence in Europe, America, Asia-Pacific, Middle East and Africa regions. It operates through its subsidiaries such as Fresenius Kabi Singapore Pte Ltd. (Singapore), Fresenius Kabi India Pvt. Ltd. (India), Fresenius Kabi USA, LLC (U.S.), Fresenius Kabi Groupe France (France), Fresenius Kabi México, S.A. de C.V. (Mexico) and among others.
